Passage Bio (PASG) Receives a Buy from Chardan Capital

Tip Ranks
2025.11.12 07:15
portai
I'm PortAI, I can summarize articles.

Chardan Capital analyst Geulah Livshits has maintained a Buy rating on Passage Bio (PASG) with a price target of $21.00. Livshits, a 5-star analyst with a 22.2% average return and a 41.55% success rate, focuses on the Healthcare sector. Additionally, Wedbush also reiterated a Buy rating on Passage Bio with a higher price target of $32.00.

Chardan Capital analyst Geulah Livshits maintained a Buy rating on Passage Bio today and set a price target of $21.00.

Meet Your ETF AI Analyst

  • Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
  • Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.

According to TipRanks, Livshits is a 5-star analyst with an average return of 22.2% and a 41.55% success rate. Livshits covers the Healthcare sector, focusing on stocks such as Palvella Therapeutics, Lexeo Therapeutics, Inc., and Rocket Pharmaceuticals.

In a report released yesterday, Wedbush also reiterated a Buy rating on the stock with a $32.00 price target.

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer